Streetbeat News

Price Targets

TEVA

Teva Pharmaceutical Industries' stock (TEVA) has seen an increase in its trading price following an upgrade from 'Hold' to 'Buy' by Jefferies, which also raised its price target for the stock from $10 to $14.

Portfolio Pulse from Benzinga Newsdesk

January 23, 2024 | 6:24 pm

NXPI

NXP Semiconductors' stock (NXPI) is trading higher following an initiation of coverage by Cantor Fitzgerald with an Overweight rating and a price target of $260.

Portfolio Pulse from Benzinga Newsdesk

January 23, 2024 | 6:14 pm

RUN

Sunrun (NASDAQ:RUN) has been the subject of diverse analyst ratings over the past three months, with 13 analysts offering a range of opinions. The average 12-month price target is $21.46, with a high of $35.00 and a low of $12.00, marking an 8.91% decrease in the average target. Recent actions include both raised and lowered price targets and ratings, reflecting dynamic market conditions and company performance. Sunrun's financials show a -10.88% revenue decline over 3 months, a net margin of -189.9%, an ROE of -17.52%, an ROA of -5.28%, and a high debt-to-equity ratio of 1.9.

Portfolio Pulse from Benzinga Insights

January 23, 2024 | 6:01 pm

ZUO

In the last three months, 4 analysts have provided ratings on Zuora (NYSE:ZUO), with all maintaining a bullish stance. The average 12-month price target is $14.5, representing a 45% increase from the previous target of $10. Zuora's financial performance shows positive revenue growth, a strong net margin, and an excellent ROE and ROA, but a high debt-to-equity ratio. Analysts from Goldman Sachs, Needham, and Canaccord Genuity have recently updated their ratings and price targets for ZUO.

Portfolio Pulse from Benzinga Insights

January 23, 2024 | 6:01 pm

ADM

Archer-Daniels Midland (NYSE:ADM) has been the subject of 10 analyst ratings over the past three months, with a shift towards a more bearish sentiment. The average 12-month price target has been reduced by 27.15%, with the current average at $70.3. Analysts from firms including Goldman Sachs, Stifel, Barclays, Roth MKM, BMO Capital, Baird, UBS, and Morgan Stanley have lowered their price targets. ADM's financial performance shows a decline in revenue growth by -12.11% over the past 3 months, but it maintains strong net margin, ROE, and ROA figures, and a conservative debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

January 23, 2024 | 6:00 pm

SEDG

SolarEdge Technologies (NASDAQ:SEDG) has received mixed ratings from 21 financial analysts, with a current average 12-month price target of $79.28, down 32.82% from the previous $118.01. Ratings range from 'Buy' to 'Sell', with recent actions including both upgrades and downgrades. The company's financial performance shows a -13.32% decline in revenue growth, a net margin of -8.43%, ROE of -2.44%, ROA of -1.31%, and a debt-to-equity ratio of 0.29.

Portfolio Pulse from Benzinga Insights

January 23, 2024 | 6:00 pm

ALC

CZMWY

Bernstein analyst Susannah Ludwig has initiated coverage on ophthalmology companies, recommending Alcon AG (NYSE:ALC) with an Outperform rating and a price target of $94.03, while giving Carl Zeiss Meditec AG (OTC:CZMWY) an Underperform rating with a price target of $82.31. Ludwig highlights the importance of innovation in the ophthalmology market, which is valued at $34 billion with mid-single digit growth rates. Alcon is noted for its significant R&D spending, which is 1.9 times higher than its next competitor, while Zeiss, though leading in digital, must maintain high R&D spending to stay competitive. Shares of Alcon and Carl Zeiss Meditec declined by 2.34% and 0.95%, respectively, at the time of publication.

Portfolio Pulse from Priya Nigam

January 23, 2024 | 5:47 pm

FANG

Stifel analyst Derrick Whitfield has maintained a Buy rating on Diamondback Energy (NASDAQ:FANG) but has reduced the price target from $194 to $192.

Portfolio Pulse from Benzinga Newsdesk

January 23, 2024 | 5:38 pm

DVN

Stifel analyst Derrick Whitfield has maintained a Buy rating on Devon Energy (NYSE:DVN) but has reduced the price target from $77 to $75.

Portfolio Pulse from Benzinga Newsdesk

January 23, 2024 | 5:36 pm

CW

Stifel analyst Nathan Jones has maintained a Buy rating on Curtiss-Wright (NYSE:CW) and increased the price target from $243 to $244.

Portfolio Pulse from Benzinga Newsdesk

January 23, 2024 | 5:34 pm